Condition: Diagnosis · Clinical Decision-making · Artificial Intelligence (AI) in Diagnosis · Sponsor: University Hospital, Lille
The goal of this clinical trial is to learn how artificial intelligence (AI) may help doctors make diagnoses in kidney medicine. The researchers want to know whether an AI tool called a large language model (LLM) can help doctors choose the correct diagnosis more often and feel more confident in their answers. Before starting the study, the research team tested several AI models and chose one of the best performers, a GPT-5-class model set to use high reasoning effort. The main questions this study aims to answer are: 1. Do doctors make more correct diagnoses when they can see AI suggestions? 2. Does seeing AI suggestions change how confident doctors feel about their diagnosis? Researchers will compare doctors who receive AI suggestions with doctors who do not receive AI suggestions to see how the AI affects accuracy, confidence, and decision-making. Participants will complete up to 10 online clinical cases. For each case, they will: 1. Read a short medical scenario 2. Suggest up to three possible diagnoses (If in the AI group) Review the AI's suggestions and decide whether to change their answer The study will also look at how long participants take to answer each case and how the AI's performance compares to the human answers.
This description comes directly from the study's public registry record.
Raphaël BENTEGEAC, MD, MPH · +33651204000 · raphael.bentegeac@univ-lille.fr
Always discuss trial participation with your own doctor first.
| Lille University Hospital (online study) | Lille, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07352475